Skip to main content

Supported by independent educational grants from Neurocrine Biosciences and Teva Pharmaceuticals.

View a 4-part CME video series on assessing for and treating tardive dyskinesia during the COVID-19 pandemic.
A retrospective study involving 7985 veterans found which medication or medication class was associated with the highest risk of tardive dyskinesia?
Despite the impact the COVID-19 pandemic has had on psychiatry practice, a proactive, routine, and systematic assessment for tardive dyskinesia in patients taking antipsychotics is a mandate for all clinicians, Rakesh Jain, MD, MPH, said at Psych…
A study recently published in BMC Psychiatry found that antipsychotic dosage reduction in patients with bipolar and major depressive disorders was associated with an increase in all-cause and mental health-related hospitalizations.
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, is educating clinicians on the latest research and strategies for treating tardive dyskinesia during the 2020 Psych Congress Regionals meetings. He shares some of his guidance here.
Back to Top